Home > R&D Offer > Biomarkers Discovery & Validation

Biomarkers Discovery & Validation

In order to improve diagnosis, guide therapy decisions and/or predict tumor responses, CALYM researchers develop new lymphoma biomarkers (tissue, blood, imaging) in collaboration with industry.

CALYM’s Expertise for Biomarkers Development

- Discovery of new biomarkers (diagnosis, prognosis, pharmacodynamics, predictive of clinical response, surrogate, safety…)

- Clinical validation in large cohorts and registration as part of a clinical trial

- Assay development for the clinical setting (e.g. from oriented genome-wide technologies to routine technologies such as RT-MLPA)

CALYM Resources and Means

  • Access to data

- All types: genomic, transcriptomic, immunohistochemistry, imaging, clinical, etc.

  • Sources

- Pre-existing CALYM datasets

- Profiles of samples from the CALYM clinically annotated biological collections

- De novo sample collection as part of clinical trials

- Data from CALYM pre-clinical models (cell lines, mice…)

  • Analytical expertise (bioinformatics & biostatistics)

- Screening, feature selection and model construction (gene signatures, IHC algorithm…) from training set

- Validation in independent dataset

According to its Partners’ Needs, CALYM Offers to Carry out the Research and Co-development of Lymphoma Biomarkers

CALYM (and possibly its industrial partners)

- carries out the biomarker discovery phase and establishes the proof of concept
- transfers the biomarker/the technology
- carries out the clinical validation phase

CALYM’s partner (in vitro diagnosis, biotechnology, pharmaceutical company)

- products and qualifies analytically the assay (kit)
- obtains the CE marking authorization
- carries out the commercialization and distribution phase

Please Download our Leaflets of Biomarker Offer!

LYMPHOMA BIOMARKERS RESEARCH & DEVELOPMENT OFFER (.pdf)

CLASSIFICATION OF DLBCL IN ROUTINE DIAGNOSIS PRACTICE (RT-MLPA technology) (.pdf)

A COST-EFFECTIVE MULTIPLEXED TEST FOR CHROMOSOMAL TRANSLOCATION DETECTION IN TUMORS (.pdf)

 

Contact us:+33 (0)4 72 24 41 71, by e-mail
or by submitting your question in the contact form